

# Joshua Hellmann Foundation - Newborn Metabolic Screening Program

**Centre of Inborn Errors of Metabolism**  
**The Chinese University of Hong Kong**

*Last update: 15 February 2016*

## Target inborn errors of metabolism (IEM) in this program

	<u>Inborn Errors of Metabolism</u>	Disease OMIM	ACMG <sup>¶</sup> classification	Key metabolites	Incidence in Chinese <sup>\$</sup>	Confirmation test(s) <sup>§</sup>	Outcome if not diagnosed and treated on time	Treatment	Causative gene(s) (Gene OMIM)
<b>Amino Acid Disorders</b>									
1	*Phenylketonuria (PKU) (苯丙酮尿症)	#261600	Core	↑ Phe	1 in 14,515 <sup>¶</sup>	1, 2, 4, 5	MR	Diet, drugs	PAH (*612349)
2	*Maple syrup urine disease (MSUD) (楓糖尿病)	#248600	Core	↑ Leu/Ile	1 in 101,624	1, 2, 5 ± 6	MR, early death	Diet, drugs	BCKDHA (*608348)  BCKDHB (*248611)  DBT (*248610)
3	*Citrullinaemia type 1	#215700	Core	↑ Cit	1 in	1, 5	MR, early	Diet, drugs	ASS1

	(瓜氨酸血症 1 型)				118,543		death		(*603470)
4	*Argininosuccinic aciduria (精胺丁二酸酶缺乏症)	#207900	Core	↑ Cit	1 in 592,717	1, 2, 5	MR, early death	Diet, drugs	<i>ASL</i> (*608310)
5	*Homocystinuria (高胱氨酸尿症)	#236200	Core	↑ Met	NA	1, 2, 5 ± 6	MR, neuromuscular disability	Diet, drugs	<i>CBS</i> (*613381)
6	*Tyrosinaemia Type 1 (酪氨酸血症 1 型)	#276700, #276600, #276710	Core	↑ Tyr, SA	NA	1, 2, 5	MR, early death	Drugs, liver transplantation	<i>FAH</i> (*613871)
7	Arginase deficiency (精氨酸血症)	#207800	2°	↑ Arg	NA	1, 5	MR, neuromuscular disability	Diet, drugs	<i>ARG1</i> (*608313)
8 (Group)	*Defects of biopterin cofactor biosynthesis and regeneration (生物喋呤合成或再生缺陷引起的 苯丙酮尿症)	#233910 #261640 #261630 #264070	2°	↑ Phe	1 in 14,515#	1, 2, 4, 5	MR	Diet, drugs	<i>GCH1</i> (*600225) <i>PTS</i> (*612719) <i>QDRP</i> (*612676) <i>PCBD1</i> (*126090)
9	*Citrullinaemia type 2 (Citrin deficiency) (瓜氨酸血症 2 型)	#605814	2°	↑ Cit	1 in 20,000	1, 2, 5	Neonatal hepatitis	Diet	<i>SLC25A13</i> (*603859)

	<b>Organic Acid Disorders</b>								
10	*Propionic acidemia (PA) (丙酸血症)	#606054	Core	↑ C3	1 in 600,562	2, 3, 5	MR, early death	Diet, drugs	<i>PCCA</i> (*232000) <i>PCCB</i> (*232050)
11 (Group)	*Methylmalonic aciduria (MUT, cblA/B) (甲基丙二酸血症)	#251000, #251100, #251110	Core	↑ C3	1 in 101,625	2, 3, 4, 5	MR, early death	Diet, drugs	<i>MUT</i> (*609058) <i>MMAA</i> (*607481) <i>MMAB</i> (*607568)
12	*Isovaleric acidemia (IVA) (異戊酸血症)	#243500	Core	↑ C5	1 in 660,562	2, 3, 5	MR, early death	Diet, drugs	<i>IVD</i> (*607036)
13	*β-Ketothiolase deficiency (BKT) (酮硫解酶缺乏症)	#203750	Core	↑ C5OH, C5:1	NA	2, 3, 5	MR, early death	Diet, drugs	<i>ACATI</i> (*607809)
14	*Glutaric acidemia type 1 (GA1) (戊二酸血症第1型)	#231670	Core	↑ C5DC	1 in 101,625	2, 3, 5	MR, early death	Diet, drugs	<i>GCDH</i> (*608801)
15	*3-Hydroxy-3-methylglutaryl-CoA lyase deficiency (HMG) (白胺酸代谢異常症 or 三羥基三 甲基戊二酸血症)	#246450	Core	↑ C5OH	NA	2, 3, 5	Sudden/early death	Diet	<i>HMGCL</i> (*613898)
16	*Multiple carboxylase deficiency (MCD) (多發性羧化酶缺乏症)	#253270, #253260	Core	↑ C5OH	1 in 296,359	2, 3, 4, 5	MR, early death	Drugs	<i>HLCS</i> (*609018) <i>BTD</i>

									(*609019)
17	3-Methylcrotonyl-CoA carboxylase deficiency (3MCC) (3-甲基巴豆醯輔酵素羧化酵素缺乏症)	#210200, #210210	Core	↑ C5OH	1 in 18,522	2, 3, 5	MR, early death	Diet, drugs	<i>MCCC1</i> (*609010) <i>MCCC2</i> (*609014)
18	Malonic aciduria (丙二酸尿症)	#248360	2°	↑ C3DC	NA	2, 3, 5	MR	Diet, drugs	<i>MLYCD</i> (*606761)
19	3-Methylglutaconic aciduria type I (3MGA) (3型3-甲基戊二酸尿症)	#250950	2°	↑ C5OH	NA	2, 3, 5	MR, early death	Diet, drugs	<i>AUH</i> (*600529)
20 (Group)	Cbl C/D (甲基丙二酸血症)	#277400, #277410	2°	↑ C3	NA	2, 3, 5 ± 6	MR, early death	Diet, drugs	<i>MMACHC</i> (*609831) <i>C2ORF25</i> (*611935)
	<b>Fatty Acid Oxidation Disorders</b>								
21	*Primary carnitine deficiency / carnitine update defect (CUD) (卡尼丁缺乏症)	#212140	Core	↓ C0	1 in 118,543	3, 5	Sudden death/early death	Drugs	<i>SLC22A5</i> (*603377)
22	*Medium-chain acyl-CoA dehydrogenase deficiency (MCAD) (中鏈醯輔酶 A 去氫酶缺乏症)	#201450	Core	↑ C8	1 in 660,562	2, 3, 5	Sudden death/early death	Diet, drugs	<i>ACADM</i> (*607008)
23	*Very long-chain acyl-CoA dehydrogenase deficiency (VLCAD) (極長鏈醯輔酶 A 去氫酶缺乏症)	#201475	Core	↑ C14:1	NA	3, 5	Sudden death/early death	Diet, drugs	<i>ACADVL</i> (*609575)

24	Long-chain 3-hydroxyl-acyl-CoA dehydrogenase deficiency (LCHAD) (長鏈醯輔酶 A 去氫酶缺乏症)	#609016	Core	↑ C16OH	NA	3, 5	Sudden/early death	Diet	<i>HADHA</i> (*600890)
25	Trifunctional protein deficiency (TFP) (三種功能蛋白缺乏症)	#609015	Core	↑ C16OH	NA	3, 5	Sudden/early death	Diet	<i>HADHA</i> (*600890) <i>HADHB</i> (*143450)
26	*Carnitine palmitoyltransferase I deficiency (CPT1) (卡尼丁結合酵素一缺乏)	#255120	2°	↑ C0	NA	3, 5	MR, early death	Diet	<i>CTPIA</i> (*600528)
27	*Carnitine palmitoyltransferase II deficiency (CPT2) (卡尼丁結合酵素二缺乏)	#608836, #600649	2°	↑ C16	NA	3, 5	MR, early death	Diet	<i>CPT2</i> (*600650)
28	*Carnitine-acylcarnitine translocase deficiency (CACT) (卡尼丁穿透障礙)	#212138	2°	↑ C16	NA	3, 5	Sudden death/early death	Diet, drugs	<i>SLC25A20</i> (*613698)
29	*Multiple acyl-CoA dehydrogenase deficiency (Glutaric aciduria type 2, GA 2) (戊二酸血症第 2 型)	#231680	2°	↑ C4, C5	NA	2, 3, 5	Sudden death/early death	Diet, drugs	<i>ETFA</i> (*608053) <i>ETFB</i> (*130410) <i>ETFDH</i> (*231675)
30	Medium/short-chain hydroxyl-acyl-CoA dehydrogenase	#231530	2°	↑ C4OH	NA	3, 5	Asymptomatic to	Nil specific	<i>HADH</i> (*601609)

	deficiency (M/SCHAD) (中/短鏈羥酰基輔酶 A 脫氫酶缺乏症)						neuromuscular disability		
--	--	--	--	--	--	--	--------------------------	--	--

\*Conditions with an asterisk have been diagnosed and reported locally.

NA: not available

¶ACMG: American College of Medical Genetics (Ref 1 – 2). Core conditions: newborn screening for these disorders are mandated in the United States. 2° conditions: they are part of the differential diagnosis of a core condition, they are clinically significant and revealed with the screening technology but lack an efficacious treatment, or they represent incidental findings for which there is potential clinical significance.

ψThe combined incidence for phenylketonuria and biopterin cofactor biosynthesis and regeneration defects.

§Confirmation tests: 1 – plasma amino acid analysis, 2 – urine organic acid analysis, 3 – plasma free carnitine and acylcarnitine analysis, 4 – other locally available laboratory tests, 5 – genetic analysis, 6 – overseas send out tests (e.g. enzyme study)

\$Total incidence of all IEM covered in this program is estimated to be 1 in 4,122 to 1 in 5,882.(Ref 3 – 4).

### **POSITIVE screening results of the following IEM require IMMEDIATE medical attention.**

- MSUD
- Citrullinaemia type I / Argininosuccinic aciduria
- Propionic acidaemia / Methylmalonic aciduria / cbl A/B/C/D
- Isovaleric acidaemia
- β-Ketothiolase deficiency / 3-Hydroxy-3-methylglutaryl-CoA lyase deficiency / 3-Methylglutaconic aciduria type I
- MCAD
- VLCAD
- LCHAD / Trifunctional protein deficiency

- CPT II / CACT
- GA II

**POSITIVE screening results of the following IEM require URGENT medical attention (can wait until next working day if the baby is feeding well).**

- PKU / defects of biotin cofactors
- Tyrosinaemia type I
- Homocystinuria
- GA I
- Multiple carboxylase deficiency
- CUD
- CPT I

**POSITIVE screening results for IEM not listed above require medical attention as soon as possible.**

**All UNCERTAIN screening results should be followed-up by a second dried blood spot +/- additional metabolic investigations as soon as possible.**

References:

1. American College of Medical Genetics Newborn Screening Expert Group. Newborn screening: toward a uniform screening panel and system--executive summary. *Pediatrics* 2006;117(5 Pt 2):S296-307.
2. American College of Medical Genetics Report - Newborn screening: toward a uniform screening panel and system. *Genet Med* 2006;8 Suppl 1:1S-252.

3. Niu DM, Chien YH, Chiang CC, et al. Nationwide survey of extended newborn screening by tandem mass spectrometry in Taiwan. *J Inherit Metab Dis* 2010;33 (Suppl 2):S295–S305.
4. Lee HC, Mak CM, Lam CW, Yuen YP, Chan AO, Shek CC, Siu TS, Lai CK, et al. Analysis of inborn errors of metabolism: disease spectrum for expanded newborn screening in Hong Kong. *Chin Med J* 2011;124(7):983-989.

## **Publications**

1. Law LK, Lau CY, Pang CP, *et al.* An unusual case of multiple carboxylase deficiency presenting as generalized pustular psoriasis in a Chinese boy. *J Inherit Metab Dis* 1997; 20:106-107.
2. Pang CP, Law LK, Mak YT, *et al.* Investigation for inherited metabolic diseases in young hospitalised Chinese children: results over a seven-year period. *Am J Med Genet* 1997;72:417-421.
3. Law LK, *et al.* Organic acidurias in young Chinese children in Hong Kong. *J Paediatr Child Health* 1997;33(S1):263.
4. Lau D, *et al.* Glutaric aciduria type II: an unusual cause of gross motor delay. *J Paediatr Child Health* 1997;33(S1):551.
5. Hui J, *et al.* Reye's syndrome got another diagnosis. *J Paediatr Child Health* 1997;33(S1):552.
6. Tang NL, Hui J, Law LK, *et al.* Primary plasmalemmal carnitine transporter defect manifested with dicarboxylic aciduria and impaired fatty acid oxidation. *J Inherit Metab Dis* 1998;21: 423-425.
7. To KF, *et al.* Extensive pulmonary infiltration in a Chinese Niemann Pick disease type C (NPC) patient. *J Inherit Metab Dis* 1998;21(S2):118.
8. Cheung KL, *et al.* Galactosemia in a Chinese infant: a case report and review of disease incidence. *J Paediatr Child Health* 1999;35:399-400.
9. Tang NL, Ganapathy V, Wu X, *et al.* Mutations of OCTN2, an organic cation/carnitine transporter, lead to deficient cellular carnitine uptake in primary carnitine deficiency. *Hum Mol Genet* 1999;8: 655-660.
10. Tang NL, Hui J, Law LK, *et al.* Primary carnitine deficiency in the Chinese. *Chin Med J (Engl)* 2000;113: 376-380.
11. Tang NL, *et al.* X-linked adrenoleukodystrophy (ALD) in Chinese-A mutation analysis. *J Inherit Metab Dis* 2000;23(S1):253.
12. Tang NL, Hui J, Law LK, *et al.* Recurrent and novel mutations of GCDH gene in Chinese glutaric acidemia type I families. *Hum Mutat* 2000;16: 446.
13. Dekker J, Eppink MH, van Zwieten R, de Rijk T, Remacha AF, Law LK, Li AM, Cheung KL, van Berkel WJ, Roos D. Seven new mutations in the NADH-cytochrome b5 reductase gene leading to methemoglobinemia type I. *Blood* 2001;97(4):1106 -1114.
14. Tang NL, Hui J, Law LK, To KF, Mak TW, Cheung KL, *et al.* Overview of common inherited metabolic diseases in a Southern Chinese population of Hong Kong. *Clin Chim Acta* 2001;313: 195-201.
15. Horinishi A, Okubo M, Tang NL, Hui J, To KF, Mabuchi T, *et al.* Mutational and haplotype analysis of AGL in patients with glycogen storage disease type III. *J Hum Genet* 2002;47: 55-59.

16. Hui J, Fung EL, Tang NL, Chan MH, To KF, Fok TF. Diagnosing Wilson's disease in a 5-year-old child. *J Paediatr Child Health* 2002;38: 412-413.
17. Wong PN, *et al*. Primary hyperoxaluria: a rare but important cause of nephrolithiasis. *Hong Kong Med J* 2002;8(3):202-206.
18. Tang NL, Hwu WL, Chan RT, Law LK, Fung LM, Zhang WM. A Founder mutation (R254X) of SLC22A5 (OCTN2) in Chinese primary carnitine deficiency patients. *Hum Mutat*. 2002;20(3):232.
19. Tang NL, Hui J, Yong CK, Wong LT, Applegarth DA, Vallance HD, *et al*. A genomic approach to mutation analysis of holocarboxylase synthetase gene in three Chinese patients with late-onset holocarboxylase synthetase deficiency. *Clin Biochem* 2003;36: 145-149.
20. Tang NL, Hui J, Young E, Worthington V, To KF, Cheung KL, *et al*. A novel mutation (G233D) in the glycogen phosphorylase gene in a patient with hepatic glycogen storage disease and residual enzyme activity. *Mol Genet Metab* 2003;79:142-145.
21. Law LK, Tang NL, Hui J, Lam CW, Fok TF. 3-methylglutaconic aciduria in a Chinese patient with glycogen storage disease Ib. *J Inherit Metab Dis* 2003;26:705-709.
22. Law LK. *et al*. 3-Methylglutaconic aciduria in glycogen storage disease type 1 – plausible origin and potential clinical use. *J Inherit Metab Dis* 2003;26(S2):51.
23. Wong PN, Law EL, Tong GM, Mak SK, Lo KY, Wong AK. Diagnosis of primary hyperoxaluria type 1 by determination of peritoneal dialysate glycolic acid using standard organic-acids analysis method. *Perit Dial Int* 2003;23(Suppl 2):S210-213.
24. Law LK, Tang NL, Lam CW, Tong MK, Mak TW, Zhang WM, Wanders RJ. Novel missense mutations in the first Chinese patient with very-long-chain acyl-CoA dehydrogenase deficiency. *Clin Chim Acta* 2007;375(1-2):173-174.
25. Law LK, Tang NL, Hui J, Ho CS, Ruiter J, Fok TF, *et al*. A novel functional assay for simultaneous determination of total fatty acid beta-oxidation flux and acylcarnitine profiling in human skin fibroblasts using (2)H(31)-palmitate by isotope ratio mass spectrometry and electrospray tandem mass spectrometry. *Clin Chim Acta* 2007;382: 25-30.
26. Law LK, *et al*. Detection of fatty acid oxidation defects using simultaneous measurements of total fatty acid β-oxidation flux and acylcarnitine profiling in fibroblasts cultured with 2H31-palmitate by isotope ratio mass spectrometry and electrospray tandem mass spectrometry. *J Inherit Metab Dis* 2007;30(Suppl 1):46.
27. Hwu WL, Chien YH, Tang NL, Law LK, Lin CY, Lee NC. Deficiency of the carnitine transporter (OCTN2) with partial N-acetylglutamate synthase (NAGS) deficiency. *J Inherit Metab Dis* 2007;30(5):816.

28. Law LK, *et al*. Total acylcarnitine level determined by in-vitro probe assay using 2H31-palmitate can differentiate carnitine uptake defect from other fatty acid oxidation disorders. *J Inherit Metab Dis* 2007;30(Suppl 1):47.
29. Law LK, Tang NL, Hui J, Fung SL, Ruiter J, Wanders RJ, *et al*. Novel mutations in ETFDH gene in Chinese patients with riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency. *Clin Chim Acta* 2009;404: 95-99.
30. Law LK, *et al*. A practical approach for the diagnosis of prevalent fatty acid beta oxidation defects presenting with neuromuscular symptoms among Southern Chinese. *Brainchild* 2009;10:40-52.
31. Hui J, Tang N. Scaly rash. *J Paediatr Child Health* 2010;46(7-8):441,452.
32. Hui J, To KF, Tang NL, Yau HC, Law EL, Ng PC. Combination of hyperammonaemia and tachyarrhythmia in a newborn with carnitine-acylcarnitine translocase deficiency. *Hong Kong J Paediatr (new series)* 2010;15:307-310.
33. Lau CK, Hui J, Fong FN, To KF, Fok TF, Tang NL, *et al*. Novel mutations in PHKA2 gene in glycogen storage disease type IX patients from Hong Kong, China. *Mol Genet Metab* 2011;102:222-225.
34. Lee NC, Tang NL, Chien YH, Chen CA, Lin SJ, Chiu PC, Huang AC, Hwu WL. Diagnoses of newborns and mothers with carnitine uptake defects through newborn screening. *Mol Genet Metab* 2010;100:46-50.
35. Kwok JS, Fung SL, Lui GC, Law EL, Chan MH, Leung CB, Tang NL. CBS gene mutations found in a Chinese pyridoxine-responsive homocystinuria patient. *Pathology* 2011;43(1):81-83.
36. Hui J, Law E, Chung C, Fung S, Yuen P, Tang N. The first reported HLCS gene mutation causing holocarboxylase synthetase deficiency in a Vietnamese patient. *World J Pediatr* 2012;8(3):278-280.
37. Kwok JS, Yuen CL, Law LK, Tang NL, Cherk SW, Yuen YP. A novel ALDH5A1 mutation in a patient with succinic semialdehyde dehydrogenase deficiency. *Pathology* 2012;44(3):280-282.
38. Hui J, Tang NL, Li CK, Law LK, To KF, Yau P, Fung SL, Chong JS, Tsung L, Chiang G, Fung E, Cheung KL, Yeung WL, Fok TF. Inherited metabolic diseases in the Southern Chinese population: spectrum of diseases and estimated incidence from recurrent mutations. *Pathology* 2014;46(5):375-382.